Patents by Inventor Michael D. Macklin

Michael D. Macklin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7022320
    Abstract: Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding at least two M. tuberculosis antigens. Vectors and compositions containing these molecules are also described. In addition, compositions containing a cocktail of recombinant nucleic acid molecules having a sequence or sequences encoding one or more M. tuberculosis antigens are described. Methods of eliciting an immune response using these molecules and compositions are also described.
    Type: Grant
    Filed: February 9, 2000
    Date of Patent: April 4, 2006
    Assignee: PowderJect Vaccines, Inc.
    Inventors: Michael D. Macklin, Deborah L. Fuller
  • Publication number: 20020165176
    Abstract: Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding an influenza virus M2 antigen. Vectors and compositions containing these molecules are also described. Methods for eliciting an immune response using these molecules and compositions are also described.
    Type: Application
    Filed: April 30, 2001
    Publication date: November 7, 2002
    Inventors: Joel R. Haynes, Michael D. Macklin, Lendon G. Payne
  • Patent number: 5661132
    Abstract: A DNA molecule encoding a secretable mature epidermal growth factor (EGF) polypeptide is delivered to a skin wound. The cells that take up the recombinant DNA construct express soluble EGF that is secreted into surrounding fluid. The presence of the EGF accelerates, by a statistically significant amount, the healing time of a wound treated in this manner.The DNA molecule can be a genetic construction that expresses an EGF encoding portion that differs from the naturally occurring EGF precursor gene in that the only coding region retained from the precursor gene is that of the mature EGF polypeptide. Amino-terminal EGF-like repeats and the carboxy-terminal hydrophobic sequence that anchors natural EGF to the cell membrane are not present in the genetic construction.
    Type: Grant
    Filed: November 22, 1994
    Date of Patent: August 26, 1997
    Assignee: Auragen, Inc.
    Inventors: Elof Eriksson, Christophe Andree, William F. Swain, Michael D. Macklin